Galderma presents new scientific dermatology data at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, March 27–31. The company shares 22 abstracts, including late‑breaking data and oral presentations. These sessions span therapeutic dermatology and skin care science.
Atopic dermatitis presentations include late-breaking data
Galderma presents late‑breaking data on Nemluvio® (nemolizumab) for moderate‑to‑severe atopic dermatitis across different patient groups. The study includes paediatric pharmacokinetic, safety, and efficacy findings.
One oral presentation examines itch and skin responses maintained through 104 weeks of treatment.
Additional posters show the long‑term safety and efficacy of Nemluvio in adolescents. Another poster focuses on patients with partial or minimal skin response at 16 weeks.
Acne research includes decades of innovation
Galderma also highlights four posters on AKLIEF® (trifarotene) cream and acne. These highlights showcase four generations of retinoid innovation. Real-world evidence will evaluate customised trifarotene regimens and their effects on skin quality. One poster will examine facial and truncal acne treatment in Indian patients.
Sensitive skin and AI research headline dermatological skincare
Nine dermatological skincare presentations explore sensitive, acne‑prone, and mature skin topics.
One oral presentation shows how artificial intelligence identifies high‑risk factors for sensitive skin.
Another oral abstract will share survey results on acne management following isotretinoin therapy.
Five e‑posters evaluate Cetaphil product performance in various skin types. Topics include time to itch relief with Cetaphil Restoraderm products and efficacy in mature skin. Presentations also assess the mildness of Cetaphil Gentle Skin Cleanser.
Company spotlight on evidence and diverse needs
Galderma said its data presentations demonstrate its commitment to dermatology science and patient needs. The company emphasised delivering effective solutions for diverse skin conditions through rigorous clinical evidence.
Galderma’s broad dermatology portfolio at AAD
Data at the meeting illustrate Galderma’s leadership in therapeutic dermatology and skin care science.
The presentations aim to support clinicians with practical insights and improved patient outcomes.
Galderma continues to advance dermatology through evidence‑driven research and global clinical engagement.